← Back to headlines
Fulcrum Therapeutics Merges with Slate in $245M Migraine Biotech Deal
Fulcrum Therapeutics has announced a merger with Slate, a biotech company focused on migraine treatments, in a deal valued at $245 million.
17 Aug, 13:02 — 17 Aug, 13:02
Sources
Showing 1 of 1 sources
